Full-Time

Field Engineering Specialist

Multiple Teams

Posted on 9/9/2025

Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

Compensation Overview

$68.9k - $127.9k/yr

+ Bonus

St. Louis, MO, USA

Hybrid

The role requires daily travel with up to 30% overnight travel expected. The territory includes the St. Louis Metro Area, Quincy, IL, Peoria, IL, Cape Girardeau, MO, and Paducah, KY.

Category
Mechanical Engineering (1)
Requirements
  • High school diploma and 2 years of technical school or equivalent military training or equivalent work experience
  • 5 years of progressive experience repairing or servicing mechanical/system hardware and software, or networking/wireless networking or a Bachelor’s degree in Biomedical Engineering, Mechanical Engineering, Electrical Engineering, Chemistry or related field plus 1-2 years of progressive experience repairing or servicing complex mechanical/system hardware and software, or networking/wireless networking
  • Successful completion of training or certification as defined by Roche Diagnostics Services Leadership and policy
  • Ability to travel, including some overnight travel, is required
Responsibilities
  • Provides routine technical support to customers on operational and maintenance aspects of system equipment
  • Performs on-site service, repair, and/or installation of company products - This may include any aspect of field support and is not limited to mechanical/system hardware and software, networking/wireless networking
  • Serves as customer contact on routine technical and service-related problems
  • Schedules and performs preventative maintenance per department policy
  • Monitors customer equipment performance and can respond and resolve most routine issues
  • Refers complex problems and issues to higher levels
  • Receives training and delivers service within the normal scope of the position
  • Follows documented practices, policies, and procedures in providing repair and installation support
  • Diagnoses mechanical, hardware, software, and system failure using established procedures
  • Determines the most cost-effective repair/resolution to minimize customer downtime
  • Provides analysis, feedback, and recommendations on product failure trends and service ability issues
  • Documents all activity in a manner compliant with the company’s quality procedures
  • Is responsible for maintaining and continuously improving the quality system and achieving quality objectives through daily actions
  • Is responsible for ensuring and maximizing customer satisfaction with Roche equipment and related products
  • Promotes effective, positive, and productive communication among the team to maximize the satisfaction of the customer base
  • Manages customer accounts at a level that promotes goodwill, confidence, and credibility to exceed customer expectations in terms of product, service, and support quality
  • Identifies revenue-generating and cost-saving opportunities, implements the Roche Diagnostics service agreement policy, and seeks out opportunities to market service contracts to existing customers
  • Maintains expenses within departmental guidelines and controls inventory and all company property
Desired Qualifications
  • Advanced knowledge of electronics, electro-mechanical systems, and information technology
  • Knowledge of basic chemistry
  • Ability to train, mentor and serve as the expert technical resource for lower level staff
  • Effective customer service skills, which includes a positive attitude, helpful customer interaction, and maintenance of ongoing customer relationships
  • Effective time-management, organization and prioritization skills
  • Effective written/verbal communication skills
  • Ability to work after hours, provide weekend and holiday support on a rotational basis within an assigned territory and/or geographic region and be on call 24/7 during rotation

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Simplify Jobs

Simplify's Take

What believers are saying

  • PathAI can strengthen AI pathology workflows and biomarker discovery.
  • Elecsys pTau217 expands Roche's Alzheimer diagnostics beyond specialist laboratory settings.
  • Nurix collaboration deepens Roche's reach into protein degradation and hematology.

What critics are saying

  • Swiss franc strength keeps distorting reported growth and investor perception.
  • Patent expirations on older medicines force rapid replacement from newer assets.
  • CT-388 must beat Novo Nordisk and Eli Lilly to matter.

What makes Roche unique

  • Roche combines pharmaceuticals, diagnostics, and digital pathology across one healthcare platform.
  • Founded in Basel in 1896, Roche built scale through branded medicines.
  • Genentech integration made Roche the world's largest biotechnology company.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Roche who can refer or advise you

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.

INACTIVE